Sutro Biopharma Announces Proposed Public Offering of 5 Million Shares of Common StockPRNewsWire • 12/07/20
Sutro Biopharma Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at the 62nd American Society of Hematology Annual MeetingPRNewsWire • 12/07/20
Sutro Biopharma: 7 Things for STRO Stock Investors to Know About the Biotech CompanyInvestorPlace • 12/04/20
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian CancerPRNewsWire • 12/03/20
Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian CancerPRNewsWire • 11/24/20
Sutro Biopharma Announces the Appointment of Diana Landa as Vice President of Regulatory Affairs and Annie Chang as Head of Investor RelationsPRNewsWire • 11/18/20
Sutro Biopharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights and DevelopmentsPRNewsWire • 11/05/20
Sutro Biopharma Presents Promising STRO-002 Interim Phase 1 Clinical Data in Ovarian Cancer at the 2020 IGCS Annual Global MeetingPRNewsWire • 09/09/20
Sutro Biopharma Announces Promising STRO-002 Interim Phase 1 Clinical Data in Ovarian Cancer and Presentation at the 2020 IGCS Annual Global MeetingPRNewsWire • 09/02/20
Sutro Biopharma Earns Clinical Supply Milestone Payment from Merck KGaA, Darmstadt, Germany for Novel Bispecific Antibody Drug Conjugate Targeting Solid TumorsPRNewsWire • 08/25/20
Sutro Biopharma to Present at the 2020 Wedbush PacGrow Healthcare Virtual ConferencePRNewsWire • 08/10/20
Sutro Biopharma Presents New Preclinical Data at 2020 AACR Virtual Annual Meeting II Suggesting Synergy between its STRO-002 Antibody-Drug Conjugate and Immune Checkpoint Inhibitors Resulting in Tumor Regression and Adaptive Anti-Tumor ImmunityPRNewsWire • 06/22/20
Sutro Biopharma to Present New Preclinical Data on its STRO-002 Antibody-Drug Conjugate at the Upcoming AACR 2020 Virtual Meeting on June 22, 2020PRNewsWire • 06/09/20
Sutro Biopharma Expands Senior Management with the Additions of Vice President of Clinical Development and Vice President of Finance and ControllerPRNewsWire • 05/21/20
Sutro Biopharma Adds Two Exceptional Leaders to Advisory Boards-- Carlos Paya, MD, PhD, and Lainie Martin, MDPRNewsWire • 05/21/20
Sutro Biopharma Announces Closing of $98.0 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional SharesPRNewsWire • 05/14/20